Growth Metrics

Prelude Therapeutics (PRLD) Change in Cash (2024 - 2026)

Prelude Therapeutics' Change in Cash history spans 3 years, with the latest figure at -$13.5 million for Q1 2026.

  • On a quarterly basis, Change in Cash fell 148.57% to -$13.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$19.3 million, a 224.16% decrease, with the full-year FY2025 number at $22.0 million, up 271.44% from a year prior.
  • Change in Cash hit -$13.5 million in Q1 2026 for Prelude Therapeutics, down from -$12.3 million in the prior quarter.
  • Over the last five years, Change in Cash for PRLD hit a ceiling of $27.8 million in Q1 2025 and a floor of -$16.7 million in Q3 2024.
  • Historically, Change in Cash has averaged -$482666.7 across 3 years, with a median of -$584000.0 in 2024.
  • The widest YoY moves for Change in Cash: up 4859.42% in 2025, down 1016.12% in 2025.
  • Tracing PRLD's Change in Cash over 3 years: stood at $1.3 million in 2024, then tumbled by 1016.12% to -$12.3 million in 2025, then decreased by 9.97% to -$13.5 million in 2026.
  • Business Quant data shows Change in Cash for PRLD at -$13.5 million in Q1 2026, -$12.3 million in Q4 2025, and $21.0 million in Q3 2025.